module Importer; module Illumina
  module RowsToIgnore
    ROWS = [
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_E749DELLRE",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_S752DELLREATS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_S752DELLREATS",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "S752_I759DELSPKANKEI",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "S752_I759DELSPKANKEI",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_A750DELELREA",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_A750DELELREA",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751>I",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751>I",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751>I",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751DELELREAT",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a phase 3 (EURTAC) study of 174 non-small cell lung cancer patients with EGFR mutations (exon 19 deletions or L858R), including 160 lung adenocarcinoma patients, improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751DELELREAT",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_T751DELELREAT",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751DELELREAT",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751>A",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751>A",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_T751>A",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751>A",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_S752>A",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_S752>A",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_S752>A",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_S752>A",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746V",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_A750>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_A750>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_A750>P",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_A750>P",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_T751DELLREAT",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_T751DELLREAT",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_T751DELLREAT",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_T751DELLREAT",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_T751>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_T751>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_T751>Q",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_T751>Q",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_S752>D",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_S752>D",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_S752>D",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_S752>D",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_T751>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_T751>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_T751>P",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_T751>P",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_P753>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_P753>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_P753>Q",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_P753>Q",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_T751>S",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_T751>S",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression-free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_T751>S",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_T751>S",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "L747_P753DELINSS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_P753DELINSS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_P753DELINSS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_P753DELINSS",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L858R",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L858R",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L858R",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747FS*10",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747FS*10",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747FS*10",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751>VA",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_T751>VA",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751>VA",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751>VA",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "L747_S752INSQ",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "L747_S752INSQ",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "L747_S752INSQ",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_S752>I",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_S752>I",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_S752>I",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_S752>I",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751>V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751>V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_T751>V",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751>V",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_A750>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_A750>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_A750>IP",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_A750>IP",
        disease: "Lung Squamous Cell Carcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_T751>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_T751>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_T751>IP",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_T751>IP",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "E746_P753>VS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was treated with erlotinib as first-line treatment and experienced improvement within one week; the patient has remained stable after one year of therapy.",
        variant: "E746_P753>VS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "27569104",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "E746_P753>VS",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",
        variant: "E746_P753>VS",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "27566387",
        drug: "Erlotinib"
      },
      {
        description: "In the European Tarceva versus Chemotherapy (EURTAC) study, 86 advanced NSCLC  patients with EGFR mutations (exon 19 deletions or L858R) treated with erlotinib had improved progression-free survival compared to 87 patients treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",
        variant: "K745_E749DELKELRE",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "22285168",
        drug: "Erlotinib"
      },
      {
        description: "A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493, 46% lung adenocarcinoma, 44% lung squamous cell carcinoma) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.",
        variant: "K745_E749DELKELRE",
        disease: "Lung Adenocarcinoma",
        pubmed_id: "21969500",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_A750>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_T751DELLREAT",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_T751>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_S752>D",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_T751>P",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_P753>Q",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_T751>S",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_P753DELINSS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L858R",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_T751>VA",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "L747_S752INSQ",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_S752>I",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_T751>V",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_A750>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_T751>IP",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "E746_P753>VS",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
      {
        description: "A study of five clinical trials reported that chemotherapy nave non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib or gefitinib were associated with improved response rate (59% vs 4%; P<0.0001) and increased median overall survival (24.5 months vs 11.8 months P=0.002) as compared to patients without EGFR sensitizing mutations.",
        variant: "K745_E749DELKELRE",
        disease: "Non-small Cell Lung Carcinoma",
        pubmed_id: "19671843",
        drug: "Erlotinib"
      },
    ]
  end
end;end
